Header Logo

Connection

MILIND JAVLE to Cholangiocarcinoma

Back to Details
This is a "connection" page, showing publications MILIND JAVLE has written about Cholangiocarcinoma.
MILIND JAVLE
Connection Strength
12.114
Cholangiocarcinoma
  1. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist. 2024 Apr 04; 29(4):e514-e525.
    View in: PubMed
    Score: 0.668
  2. Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544.
    View in: PubMed
    Score: 0.663
  3. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors. Oncologist. 2023 Nov 02; 28(11):928-943.
    View in: PubMed
    Score: 0.649
  4. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist. 2022 Oct 01; 27(10):874-883.
    View in: PubMed
    Score: 0.601
  5. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res. 2022 06 01; 28(11):2229-2236.
    View in: PubMed
    Score: 0.588
  6. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
    View in: PubMed
    Score: 0.555
  7. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr Oncol Rep. 2021 07 16; 23(9):108.
    View in: PubMed
    Score: 0.553
  8. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282.
    View in: PubMed
    Score: 0.430
  9. Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control. 2017 Jul-Sep; 24(3):1073274817729241.
    View in: PubMed
    Score: 0.418
  10. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810.
    View in: PubMed
    Score: 0.414
  11. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
    View in: PubMed
    Score: 0.351
  12. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol. 2007 Nov; 14(11):3202-9.
    View in: PubMed
    Score: 0.211
  13. Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology. 2007 Jul-Aug; 54(77):1339-44.
    View in: PubMed
    Score: 0.209
  14. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol. 2006 Nov; 21(11):1744-51.
    View in: PubMed
    Score: 0.200
  15. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology. 2004 Nov-Dec; 51(60):1653-7.
    View in: PubMed
    Score: 0.174
  16. Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress? Ann Surg Oncol. 2024 May; 31(5):3062-3068.
    View in: PubMed
    Score: 0.165
  17. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight. 2024 Jan 23; 9(2).
    View in: PubMed
    Score: 0.165
  18. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. Clin Cancer Res. 2023 12 01; 29(23):4853-4862.
    View in: PubMed
    Score: 0.163
  19. Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 Feb; 80(2):322-334.
    View in: PubMed
    Score: 0.163
  20. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
    View in: PubMed
    Score: 0.161
  21. What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma? Cancer J. 2023 Sep-Oct 01; 29(5):272-278.
    View in: PubMed
    Score: 0.160
  22. The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. JCO Precis Oncol. 2023 08; 7:e2200594.
    View in: PubMed
    Score: 0.159
  23. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst. 2023 07 06; 115(7):870-880.
    View in: PubMed
    Score: 0.159
  24. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6558-6566.
    View in: PubMed
    Score: 0.158
  25. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332.
    View in: PubMed
    Score: 0.156
  26. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer. 2023 05 15; 129(10):1537-1546.
    View in: PubMed
    Score: 0.155
  27. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes? HPB (Oxford). 2023 04; 25(4):472-480.
    View in: PubMed
    Score: 0.154
  28. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022 07 01; 128(13):2529-2539.
    View in: PubMed
    Score: 0.146
  29. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. J Mol Diagn. 2022 04; 24(4):351-364.
    View in: PubMed
    Score: 0.144
  30. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol. 2022 02; 6:e2100197.
    View in: PubMed
    Score: 0.144
  31. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol. 2022 Mar; 40:101696.
    View in: PubMed
    Score: 0.143
  32. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022 03; 22(3):823-832.
    View in: PubMed
    Score: 0.143
  33. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
    View in: PubMed
    Score: 0.142
  34. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677.
    View in: PubMed
    Score: 0.141
  35. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2022 02; 12(2):402-415.
    View in: PubMed
    Score: 0.140
  36. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol. 2021 08; 5.
    View in: PubMed
    Score: 0.139
  37. Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations. Carcinogenesis. 2021 04 17; 42(3):436-441.
    View in: PubMed
    Score: 0.136
  38. Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Ann Surg Oncol. 2021 Oct; 28(11):6725-6735.
    View in: PubMed
    Score: 0.134
  39. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Oct; 16(30):2375-2384.
    View in: PubMed
    Score: 0.129
  40. Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020 06; 104(6):1125-1130.
    View in: PubMed
    Score: 0.128
  41. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
    View in: PubMed
    Score: 0.127
  42. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev. 2020 Jun; 86:101998.
    View in: PubMed
    Score: 0.126
  43. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chin Clin Oncol. 2020 Feb; 9(1):8.
    View in: PubMed
    Score: 0.125
  44. Preoperative drainage for perihilar cholangiocarcinoma. Lancet Gastroenterol Hepatol. 2019 01; 4(1):10-11.
    View in: PubMed
    Score: 0.115
  45. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
    View in: PubMed
    Score: 0.113
  46. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 05; 3(5):337-348.
    View in: PubMed
    Score: 0.110
  47. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017 Feb; 104(3):267-277.
    View in: PubMed
    Score: 0.101
  48. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2017 04 15; 123(8):1354-1362.
    View in: PubMed
    Score: 0.101
  49. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847.
    View in: PubMed
    Score: 0.099
  50. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.094
  51. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20; 34(3):219-26.
    View in: PubMed
    Score: 0.093
  52. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016 May; 69(5):403-8.
    View in: PubMed
    Score: 0.093
  53. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
    View in: PubMed
    Score: 0.077
  54. Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene. 2013 Aug 08; 32(32):3722-31.
    View in: PubMed
    Score: 0.075
  55. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci. 2011 May; 56(5):1557-64.
    View in: PubMed
    Score: 0.067
  56. Cholangiocarcinoma: an endoscopist's perspective. Expert Rev Gastroenterol Hepatol. 2010 Oct; 4(5):601-11.
    View in: PubMed
    Score: 0.065
  57. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007 Apr; 11(4):445-51.
    View in: PubMed
    Score: 0.051
  58. Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer. 2006; 37(1):27-34.
    View in: PubMed
    Score: 0.047
  59. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma - Authors' reply. Lancet Gastroenterol Hepatol. 2018 08; 3(8):529-530.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.